Based on our early study of CXCR4 expression decreased by metapristone in ovarian cancer [17], we hypothesized that the combinatory chemotherapy strategy using sorafenib in combination with metapristone could strengthen anti-cancer activity of sorafenib and suppress potential resistance to sorafenib in HCC. The gene discussed is CXCR4; the disease is hepatocellular carcinoma.